• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠状动脉支架政策对上海急性冠状动脉综合征患者经皮冠状动脉介入治疗风险的影响:真实世界证据。

The effect of coronary stent policies on the risk of percutaneous coronary intervention among acute coronary syndrome patients in Shanghai: Real-world evidence.

机构信息

Health Statistics Department, Shanghai Statistics Center for Health, Shanghai, People's Republic of China.

School of Public Health, NHC Key Laboratory of Health Technology Assessment (Fudan University), Fudan University, Shanghai, People's Republic of China.

出版信息

PLoS One. 2024 Apr 1;19(4):e0301448. doi: 10.1371/journal.pone.0301448. eCollection 2024.

DOI:10.1371/journal.pone.0301448
PMID:38557900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10984406/
Abstract

OBJECTIVE

This study aimed to analyze the effect of coronary stent policies implemented in Shanghai on the risk of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) inpatients based on real-world data.

METHODS

Two retrospective cohorts of inpatients with a first diagnosis of ACS who had undergone PCI for the first time in the previous year in Shanghai hospitals were examined (one for the postpolicy period and the other for the prepolicy period). χ2 tests were used to compare categorical variables between the two cohorts. Single- and multivariate Cox proportional hazards models were used to compare the risk of major adverse cardiovascular events (MACEs) between the two cohorts.

RESULTS

A total of 31,760 ACS patients were included in this study. The proportion of ACS inpatients who had at least one bid-winning stent and 3 or more coronary stents implanted for first-time PCI in the postpolicy cohort was higher than that in the prepolicy cohort (86.52% vs. 55.67% and 6.27% vs. 4.39%, respectively; all p values < 0.0001). The single- and multivariate Cox proportional hazards models revealed that the unadjusted and adjusted hazard ratios for MACEs at 1 year after PCI for the postpolicy cohort relative to the prepolicy cohort were 0.869 (P<0.0001) and 0.814 (P = 0.0007), respectively.

CONCLUSIONS

The implementation of coronary stent policies changed coronary stent utilization but had no significant adverse effects on the risk of PCI among ACS patients in Shanghai in the short term. However, the reasons for changes in the number of coronary stents implanted should be analyzed and addressed in the future.

摘要

目的

本研究旨在基于真实世界数据,分析上海实施冠状动脉支架政策对急性冠状动脉综合征(ACS)住院患者经皮冠状动脉介入治疗(PCI)风险的影响。

方法

对前一年在上海医院首次接受 PCI 的 ACS 住院患者的两个回顾性队列(一个为政策后队列,另一个为政策前队列)进行检查。使用 χ2 检验比较两个队列之间的分类变量。使用单因素和多因素 Cox 比例风险模型比较两个队列之间主要不良心血管事件(MACE)的风险。

结果

本研究共纳入 31760 例 ACS 患者。政策后队列中至少有一个中标支架和首次 PCI 植入 3 个或更多冠状动脉支架的 ACS 住院患者比例高于政策前队列(86.52%比 55.67%和 6.27%比 4.39%;所有 P 值均<0.0001)。单因素和多因素 Cox 比例风险模型显示,政策后队列 PCI 后 1 年 MACE 的未调整和调整危险比相对于政策前队列分别为 0.869(P<0.0001)和 0.814(P=0.0007)。

结论

冠状动脉支架政策的实施改变了冠状动脉支架的使用情况,但在短期内对上海 ACS 患者 PCI 风险没有显著的不良影响。然而,未来应分析和解决冠状动脉支架植入数量变化的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2c/10984406/cbc902d8867f/pone.0301448.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2c/10984406/cbc902d8867f/pone.0301448.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2c/10984406/cbc902d8867f/pone.0301448.g001.jpg

相似文献

1
The effect of coronary stent policies on the risk of percutaneous coronary intervention among acute coronary syndrome patients in Shanghai: Real-world evidence.冠状动脉支架政策对上海急性冠状动脉综合征患者经皮冠状动脉介入治疗风险的影响:真实世界证据。
PLoS One. 2024 Apr 1;19(4):e0301448. doi: 10.1371/journal.pone.0301448. eCollection 2024.
2
Do coronary stent policies affect the cost-effectiveness of percutaneous coronary intervention among patients with acute coronary syndrome in Shanghai? A retrospective cohort study based on real-world and propensity score-matched data.基于真实世界和倾向评分匹配数据的回顾性队列研究:冠状动脉支架政策是否影响上海急性冠脉综合征患者经皮冠状动脉介入治疗的成本效益?
BMJ Open. 2024 Jun 19;14(6):e083456. doi: 10.1136/bmjopen-2023-083456.
3
Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study.基线血浆纤维蛋白原与急性冠状动脉综合征患者经皮冠状动脉介入治疗后血红蛋白 A1c 和 2 年主要不良心血管事件相关:一项单中心前瞻性队列研究。
Cardiovasc Diabetol. 2019 Apr 23;18(1):52. doi: 10.1186/s12933-019-0858-5.
4
Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: Single-center, retrospective cohort study.血栓调节蛋白可预测急性冠状动脉综合征患者的二次事件发生率:单中心回顾性队列研究。
J Cardiol. 2018 Dec;72(6):494-500. doi: 10.1016/j.jjcc.2018.05.006. Epub 2018 Jun 7.
5
Double product reflects the association of heart rate with MACEs in acute coronary syndrome patients treated with percutaneous coronary intervention.双乘积反映了接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者心率与主要不良心血管事件之间的关联。
BMC Cardiovasc Disord. 2017 Dec 2;17(1):284. doi: 10.1186/s12872-017-0714-z.
6
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT.生物可吸收雷帕霉素洗脱支架与其他雷帕霉素洗脱支架在非 ST 段抬高型急性冠脉综合征中的比较:GLASSY 和 TWILIGHT 的汇总分析。
Int J Cardiol. 2023 Jul 15;383:24-32. doi: 10.1016/j.ijcard.2023.04.027. Epub 2023 Apr 18.
7
Comparison of long-term outcomes in STEMI and NSTE-ACS after coronary stent placement: an analysis in a real world BMS and DES population.经皮冠状动脉介入治疗后 STEMI 和 NSTE-ACS 患者长期结局的比较:真实世界 BMS 和 DES 人群分析。
Int J Cardiol. 2013 Sep 1;167(5):2082-7. doi: 10.1016/j.ijcard.2012.05.064. Epub 2012 Jun 2.
8
Prevalence, correlation and clinical outcome of intra-procedural stent thrombosis in patients undergoing primary percutaneous coronary intervention for acute coronary syndrome.急性冠脉综合征患者行直接经皮冠状动脉介入治疗术中支架内血栓形成的发生率、相关性及临床转归。
J Interv Cardiol. 2013 Jun;26(3):215-20. doi: 10.1111/joic.12029. Epub 2013 Apr 3.
9
The Outcome of Percutaneous Coronary Intervention for Significant Atherosclerotic Lesions in Segment Proximal to Myocardial Bridge at Left Anterior Descending Coronary Artery.经皮冠状动脉介入治疗对左前降支冠状动脉心肌桥近端显著动脉粥样硬化病变的疗效
Int Heart J. 2018 May 30;59(3):467-473. doi: 10.1536/ihj.17-179. Epub 2018 May 20.
10
Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.评估 LDL-C/HDL-C 比值对经皮冠状动脉介入治疗和药物洗脱支架置入术后急性冠脉综合征患者一年临床结局的预测价值。
Lipids Health Dis. 2019 Feb 2;18(1):40. doi: 10.1186/s12944-019-0979-6.

引用本文的文献

1
Do coronary stent policies affect the cost-effectiveness of percutaneous coronary intervention among patients with acute coronary syndrome in Shanghai? A retrospective cohort study based on real-world and propensity score-matched data.基于真实世界和倾向评分匹配数据的回顾性队列研究:冠状动脉支架政策是否影响上海急性冠脉综合征患者经皮冠状动脉介入治疗的成本效益?
BMJ Open. 2024 Jun 19;14(6):e083456. doi: 10.1136/bmjopen-2023-083456.

本文引用的文献

1
Improving access to medicines and beyond: the national volume-based procurement policy in China.提高药品可及性及其他方面:中国的以药品年度采购量为基础的采购政策。
BMJ Glob Health. 2023 Jul;8(7). doi: 10.1136/bmjgh-2022-011535.
2
Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.基于量的采购政策对中国具有 EGFR 突变的非小细胞肺癌第一代靶向药物使用和支出的影响:一项中断时间序列研究。
BMJ Open. 2023 Jul 5;13(7):e064199. doi: 10.1136/bmjopen-2022-064199.
3
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.
《心脏病与卒中统计数据-2023 更新:美国心脏协会报告》。
Circulation. 2023 Feb 21;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123. Epub 2023 Jan 25.
4
Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary.中国心血管健康与疾病报告 2021:概要更新
Biomed Environ Sci. 2022 Jul 20;35(7):573-603. doi: 10.3967/bes2022.079.
5
Still a Long Way to the Precision Medicine of Antiplatelet Strategy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后抗血小板策略的精准医学之路仍漫长。
Circ Cardiovasc Interv. 2022 Aug;15(8):e012261. doi: 10.1161/CIRCINTERVENTIONS.122.012261. Epub 2022 Jul 28.
6
Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.国家集中带量采购对乙型肝炎病毒抗病毒药物采购量及支出的影响
Front Pharmacol. 2022 Jun 6;13:842944. doi: 10.3389/fphar.2022.842944. eCollection 2022.
7
The cost-effectiveness of radial access percutaneous coronary intervention: A propensity-score matched analysis of Victorian data.经桡动脉入路行经皮冠状动脉介入治疗的成本效益:维多利亚州数据的倾向评分匹配分析。
Clin Cardiol. 2022 Apr;45(4):435-446. doi: 10.1002/clc.23798. Epub 2022 Feb 22.
8
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.《心脏病与卒中统计-2022 更新:美国心脏协会报告》。
Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
9
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.血管造影定量血流比指导的冠状动脉介入治疗(FAVOR III China):一项多中心、随机、假手术对照试验。
Lancet. 2021 Dec 11;398(10317):2149-2159. doi: 10.1016/S0140-6736(21)02248-0. Epub 2021 Nov 4.
10
Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials.经皮冠状动脉介入治疗中的抗血小板治疗:随机对照试验的最新证据。
Curr Opin Cardiol. 2021 Jul 1;36(4):390-396. doi: 10.1097/HCO.0000000000000879.